Novartis Terminates Development Of Aveo Antibody
Novartis has walked away from Aveo’s cachexia candidate after a turbulent week in the development of the antibody program, three years after paying $15m for development and commercialization rights.
Novartis has walked away from Aveo’s cachexia candidate after a turbulent week in the development of the antibody program, three years after paying $15m for development and commercialization rights.